Regencell Bioscience (NASDAQ:RGC) Trading Down 6.7% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price fell 6.7% during mid-day trading on Thursday . The company traded as low as $22.31 and last traded at $22.15. 45,239 shares were traded during mid-day trading, a decline of 84% from the average session volume of 291,052 shares. The stock had previously closed at $23.75.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Down 6.5%

The company’s 50 day simple moving average is $27.55 and its two-hundred day simple moving average is $25.32.

Regencell Bioscience (NASDAQ:RGC) last announced its earnings results on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new position in shares of Regencell Bioscience in the 4th quarter valued at approximately $92,000. Amundi purchased a new position in shares of Regencell Bioscience in the 1st quarter valued at approximately $219,000. Hudson Bay Capital Management LP acquired a new position in shares of Regencell Bioscience in the fourth quarter valued at about $275,000. Bank of America Corp DE increased its holdings in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares during the period. Finally, Vident Advisory LLC increased its holdings in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the period. 0.13% of the stock is owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.